After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Arcutis Biotherapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $9.27 and fluctuated between $9.60 as its day high and $8.58 as its day low. The current market capitalization of Arcutis Biotherapeutics Inc is $897.24M. A total of 3.12 million shares were traded on the day, compared to an average of 5.79M shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, ARQT has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 22 BUYs and 27 SELLs from insiders. Insiders purchased 417,638 shares during that period but sold 44,064.
In the most recent transaction, Burnett Patrick sold 1,325 shares of ARQT for 3.54 per share on Jan 02. After the transaction, the insider now owns 57,032 company shares. In a previous transaction on Nov 21, Matsuda Masaru sold 1,850 shares at 1.98 per share. ARQT shares that See Remark owns now total 46,634.
Among the insiders who bought shares, Frazier Life Sciences VIII, L. acquired of 80,000 shares on Oct 24 at a per-share price of $2.50. This resulted in the 10% Owner holding 8,764,232 shares of ARQT after the transaction. In another insider transaction, Burnett Patrick sold 1,605 shares at $7.04 per share on Aug 21. Company shares held by the insider now total 58,357.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for ARQT in the last 3 months, the mean price target is $12.00 with high estimates of $20.00 and low estimates of $6.00. In terms of 52-week highs and lows, ARQT has a high of $17.57 and a low of $1.76.
As of this writing, ARQT has an earnings estimate of -$0.78 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.48 per share and a lower estimate of -$0.96. The company reported an EPS of -$1.16 in the last quarter, which was 7.20% higher than expectations of -$1.25.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ARQT’s latest balance sheet shows that the firm has $387.06M in Cash & Short Term Investments as of fiscal 2021. There were $77.56M in debt and $33.33M in liabilities at the time. Its Book Value Per Share was $0.76, while its Total Shareholder’s Equity was $297.68M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.40.
